Amplimmune

Amplimmune is a product-driven company developing immune-based biologics to treat patients in the fields of cancer, autoimmune diseases, transplantation, and infectious diseases. The scientific founders of Amplimmune come from Johns Hopkins University, where they have identified several key immune ligands and receptors. These immune checkpoints and co-stimulatory molecules form the basis for developing a new biological treatment method that modulates critical mechanisms of the body's immune system to improve the lives of patients with abnormal immune conditions.